(781) 269-2602

info@global-cures.org

Contact

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey Instagram Icon

Meet The Team

Our Board of Directors and Scientific Advisors are experts in their fields, bringing track records of innovative thinking across disciplines and valued for their insights into solving some of the most intractable problems in medicine today.

We are well-connected internationally, and in both academic and industry circles.

We have a proven track record of "breaking silos" and cross-disciplinary thinking - so critical for addressing complex diseases and systems.

OUR MISSION

GlobalCures is a non-profit medical research organization dedicated to curing patients with cancer and other diseases by rapidly promoting clinical research on scientifically promising, readily available and cost-effective treatments.

Our strategy is to repurpose existing drugs, currently being overlooked for cancer use, due to lack of profitability.  

 

GlobalCures is about AFFORDABLE MEDICAL INNOVATION

OUR MISSION

GlobalCures is a non-profit medical research organization dedicated to curing patients with cancer and other diseases by rapidly promoting clinical research on scientifically promising, readily available and cost-effective treatments.

Our strategy is to repurpose existing drugs, currently being overlooked for cancer use, due to lack of profitability.  

 

GlobalCures is about AFFORDABLE MEDICAL INNOVATION

Our Business Model

The current for-profit business model used by pharmaceutical companies has been instrumental in the development of many innovative drugs in use today. However, for the most part, only those basic science discoveries with high potential for financial reward are developed further by for-profit companies, leaving behind many untapped opportunities ('financial orphans').

By adopting a non-profit drug development model, GlobalCures can focus on these 'financial orphans', ideas that are currently discarded. Thus GlobalCures fills an important gap and is complementary in its approach to established pharmaceutical companies, as illustrated in the table and diagram below.